Common questions about Majamil Prolongatum (FAQ)
Q: What is the main difference between Majamil Prolongatum and regular Majamil?
Official product information states that Majamil Prolongatum is a prolonged-release tablet. This means the active substance, Diclofenac, is released steadily and gradually into the bloodstream over time. This sustained action differs from regular, immediate-release Diclofenac, which releases the full amount of the medicine right away.
Q: How quickly do people typically start to notice any effect from Majamil Prolongatum?
Due to its prolonged-release design, research indicates that the rate of initial relief may be slower compared to immediate-release formulations. Official documents note that the benefit of this form is maintaining a consistent therapeutic level over an extended period.
Q: Are there any long-term research studies available for Majamil Prolongatum?
Research supports the use of the active substance, Diclofenac, for chronic conditions like arthritis. Regulatory summaries note that while the active substance has been studied for chronic conditions, data regarding long-term outcomes and comparative evidence specific to the prolonged-release formulation may be limited.
Q: Is it true that Majamil Prolongatum should be avoided if someone has a history of stomach problems?
Regulatory documents state that use is prohibited (contraindicated) for individuals with active gastrointestinal ulceration, bleeding, or perforation. Caution is necessary if an individual has a prior history of these problems, as the official product information indicates an increased risk of serious adverse events.
Q: Is Majamil Prolongatum safe to use if someone has high blood pressure?
Official warnings indicate that the medicine has been associated with causing or worsening pre-existing high blood pressure, and it may affect the performance of certain antihypertensive medicines. For individuals with cardiovascular risk factors, caution is applied, and close monitoring of blood pressure is a common recommendation for healthcare providers.
Q: What is the purpose of the coating on the Majamil Prolongatum tablet?
The tablet is film-coated and must be swallowed whole to protect the extended-release formulation. The coating is a key part of the manufacturing design that ensures the scheduled and gradual delivery of the medicine into the body.
Q: Does Majamil Prolongatum interfere with laboratory tests other than liver function?
Official adverse reaction lists note changes to blood components, such as thrombocytopenia (low platelet counts) and leukopenia (low white blood cell counts), which are measurable through laboratory tests. Additionally, the medicine can affect the plasma concentrations of other substances, requiring laboratory monitoring.
Q: Is it normal to feel a bit tired when starting Majamil Prolongatum?
Official product information lists neurological side effects such as dizziness, somnolence (drowsiness), and fatigue in some patients. Official information advises that if somnolence or dizziness occurs, patients should use caution when performing activities that require concentration.
Q: What are the most common reasons someone might stop taking Majamil Prolongatum?
Official data indicates that common reasons for discontinuing this type of medicine in clinical studies are often related to gastrointestinal side effects, such as abdominal pain or nausea. Official warnings indicate that patients should seek immediate medical assistance and stop the drug if they experience signs of serious reactions like a severe skin rash or liver problem.
Q: Can Majamil Prolongatum cause changes in sleep patterns?
Regulatory adverse reaction lists include neurological disturbances that can affect sleep. These reported effects include insomnia (difficulty sleeping), nightmares, and somnolence (drowsiness).
Q: Is Majamil Prolongatum considered a controlled substance?
Majamil Prolongatum, which contains Diclofenac, is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). According to governmental scheduling acts, this medicine is not classified as a controlled substance.
Q: Are there specific food types that are known to interact with Majamil Prolongatum?
The official product label describes the use of the medicine as preferably taken with or after food. While no specific food types are strictly prohibited, official documents note that taking it with food will delay its absorption and reduce the peak concentration of the drug in the blood.
Q: Does Majamil Prolongatum interact with common over-the-counter cold medicines?
Official warnings note that Majamil Prolongatum is not recommended for concomitant use with other systemic NSAIDs. This is important because many common over-the-counter cold and flu products contain other NSAIDs, and using both increases the risk of serious gastrointestinal side effects.
Q: If a dose is missed, what is the general guidance in official prescribing information?
General guidance, consistent with patient information leaflets, suggests that if a dose is missed, it should be taken when remembered. If it is almost time for the next scheduled dose, the common guidance is that the missed dose should be omitted. Official patient information emphasizes that a double dose should not be taken to make up for a missed dose.
Q: What information is available regarding Majamil Prolongatum use and driving ability?
Official patient safety information indicates that if a person experiences side effects such as dizziness, drowsiness, or visual disturbances, the ability to operate machinery or drive a vehicle may be affected.
Q: Does official information list Majamil Prolongatum as potentially interacting with supplements like St. John's Wort?
While St. John's Wort may not be explicitly listed on all product information, Diclofenac is processed by a specific liver enzyme (CYP2C9) that can be affected by certain herbal remedies. Official information advises that all prescription and non-prescription supplements being taken should be communicated to a healthcare provider, as comprehensive testing for every combination is often unavailable.
Q: What is the risk of dependence or addiction associated with Majamil Prolongatum, according to official sources?
Official regulatory information classifies Majamil Prolongatum as a Non-Steroidal Anti-Inflammatory Drug (NSAID). As such, it is not associated with a risk of dependence or addiction.
Q: How long does Majamil Prolongatum stay in the system after the last dose?
Diclofenac has a short elimination half-life, meaning it is quickly processed by the body. The prolonged-release formulation, however, is designed to sustain therapeutic activity over a longer period. The drug’s effects are extended by the specific tablet design and the way the body processes the substance.
Q: Can Majamil Prolongatum cause skin sensitivity to sunlight?
Official adverse reaction lists report that side effects such as photosensitivity (increased sensitivity to sunlight) have been noted in post-marketing experience. When using this medicine, official information notes that protective measures against sun exposure may be appropriate due to the potential for photosensitivity.
Q: Is Majamil Prolongatum known to affect mood or anxiety levels?
Official documentation lists neurological side effects that include changes in mood and mental state. These reported adverse reactions include anxiety, irritability, and depression.
Q: What should be done if someone experiences a severe headache while taking Majamil Prolongatum?
While mild headache is a common side effect of this medicine, if a headache becomes severe or persistent, official guidance indicates that seeking medical assistance is important. A severe headache, especially if accompanied by other symptoms like stiff neck or fever, may be a sign of a rare but serious reaction.
Q: Are there any known interactions between Majamil Prolongatum and common vitamins (like Vitamin D or C)?
There is no specific regulatory guidance that lists interactions between Majamil Prolongatum and common vitamins, such as Vitamin C or D. Official information advises that all prescription medicines, over-the-counter products, and supplements being used should be communicated to a healthcare provider.
Q: Does Majamil Prolongatum have a boxed warning in official FDA/EMA materials?
Yes, regulatory information from the FDA assigns Diclofenac a Boxed Warning. This is the most serious type of warning and alerts users to the risk of major cardiovascular thrombotic events (like heart attack and stroke) and serious gastrointestinal adverse events (like bleeding or ulcers).
Q: Can Majamil Prolongatum be taken during a cold or flu?
As an NSAID, Majamil Prolongatum can provide relief for fever and pain associated with a cold or flu. However, it is essential to ensure that no other systemic NSAIDs are taken at the same time, as these are frequently ingredients in multi-symptom cold and flu preparations.
Q: Are there specific patient monitoring recommendations for people taking Majamil Prolongatum long-term?
For patients undergoing long-term treatment, or those with existing risk factors, official regulatory documents generally recommend periodic monitoring. This typically includes checking parameters such as blood pressure and the function of the kidneys and liver.
Q: Does Majamil Prolongatum have any known effects on fertility?
Official safety documents address the potential impact on female fertility. NSAIDs, including this medicine, are associated with a potential for reversible infertility because they may delay or prevent ovulation. Official information notes that patients planning a pregnancy are advised to discuss this potential effect with their healthcare provider.
Q: What happens if someone accidentally takes two tablets instead of one?
Accidentally taking more than the prescribed amount constitutes an overdose, as it exceeds the recommended total daily limit. Overdose symptoms can range from mild effects like vomiting to severe issues such as gastrointestinal bleeding or kidney problems. Official guidance indicates that in the event of a suspected overdose, immediate medical assistance is necessary.
Q: Is there a generic version of Majamil Prolongatum available?
The active ingredient, Diclofenac sodium, is a substance widely available in generic form. Generic versions of the prolonged-release formulation are available in many markets and can often be dispensed in place of the brand name product.
Q: Are weight changes listed as a possible side effect of Majamil Prolongatum?
The official product information mentions that Diclofenac is associated with fluid retention and oedema (swelling). This fluid retention may be reflected as a change on the scale. Weight loss has been reported rarely in some post-marketing data.
Q: What information is provided about Majamil Prolongatum and breastfeeding?
Official regulatory data indicates that Diclofenac passes into breast milk in small amounts. Official information indicates that its use during breastfeeding requires careful consideration by a healthcare professional, particularly when treating a newborn or premature infant.
Q: Can Majamil Prolongatum cause temporary vision changes?
Official adverse reaction reports include visual disturbances, such as blurred vision or double vision (diplopia). These visual changes are generally reversible once the medicine is discontinued.
